SRI 37892
SRI 37892 is a small molecule compound inhibitor of Frizzled protein 7 (Fzd7) with inhibitory activity against cancer cell proliferation (IC50=2μM) . SRI 37892 significantly blocks Wnt/Fzd7 signaling. SRI 3789 can be used in the research of developing cancer therapeutic agents [1].
Product Specifications
CAS Number
1030769-75-5
UNSPSC
12352005
Target
Wnt
Type
Reference compound
Related Pathways
Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sri-37892.html
Purity
98.92
Solubility
10 mM in DMSO
Smiles
O=C(NC1=NC(C2=CC3=C(NC(CC3)=O)C=C2)=CS1)C4=CC=C(N5C6=CC=CC=C6N=C5)C=C4
Molecular Formula
C26H19N5O2S
Molecular Weight
465.53
References & Citations
[1]Zhang W, et al. Discovery of novel frizzled-7 inhibitors by targeting the receptor's transmembrane domain. Oncotarget. 2017 Sep 6;8 (53) :91459-91470.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC682060-500 1x 500 µL
PAX5 / BSAP (Early B-Cell Marker) (PAX5/2060), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC473025-100 1x 100 µL
Lymphocyte Specific Protein 1 (LSP1) / pp52 (LSP1/3025), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 